See the DrugPatentWatch profile for vascepa

According to the information provided, generic Vascepa is expected to become available in June 2022 [1]. This anticipated release is due to the expiration of the patent held by Amarin Corporation, the company that currently manufactures Vascepa [1].

The entry of a generic version of Vascepa into the market is expected to have a significant impact on the drug's costs. Generic drugs are typically less expensive than their brand-name counterparts because generic manufacturers do not have to repeat the costly research and development process [2]. As a result, the introduction of generic Vascepa could lead to a decrease in the drug's price, making it more accessible to a larger number of patients [2].

It is worth noting that the exact extent of the price reduction is difficult to predict, as it can depend on various factors, such as the number of generic manufacturers entering the market and the level of competition among them [3]. However, studies have shown that the availability of generic drugs can lead to significant cost savings for both patients and the healthcare system as a whole [3].

In summary, generic Vascepa is expected to become available in June 2022, which may result in a decrease in the drug's cost and increased accessibility for patients.

Sources:
[1] DrugPatentWatch.com. (n.d.). Vascepa (Icosapent Ethyl). Retrieved from https://www.drugpatentwatch.com/drugs/vascepa
[2] U.S. Food and Drug Administration. (2021). Generic Drugs: Questions and Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers
[3] Generic Pharmaceutical Association. (2017). Generic Drug Savings in the United States: An Updated Analysis. Retrieved from https://www.gphaonline.org/media/4233/gpha-rd-report-2017-web.pdf